Moteur de recherche d’entreprises européennes
Financement de l’UE (3 989 713 €) : Validation d’aberrations génomiques exploitables dans un réseau d’oncologie pédiatrique pour les doctorants Hor21/08/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Validation d’aberrations génomiques exploitables dans un réseau d’oncologie pédiatrique pour les doctorants
Pre-clinical drug development for paediatric cancers is very complex, resource intensive and requiring multi-disciplinary expertise and innovative approaches. The VAGABOND ITN, consisting of 12 academic and 6 non-academic partners from 8 European countries, aims to create a multidisciplinary and multi-sectoral program to validate new therapeutic interventions in paediatric cancer. This network will be sustainable embedded in the ITCC (Innovative Treatments for Children with Cancer) Consortium. The VAGABOND ITN will focus on 15 cutting-edge research projects studying molecular, epigenetic and immunological targets. All projects will (partly) include target identification, in vitro and in vivo validation, compound testing and preparation for clinical implementation. This consortium will highly stimulate international education and multi-disciplinary exchange of expertise in the different steps of pre-clinical drug development. This setting provides an opportunity for a unique European training network in which early stage researchers are equipped with a broad knowledge in pre-clinical drug development. Through this network students will gain access to other leading academic research groups, specialized multi-sectoral companies and the most innovative techniques and insights in the complexity of translational medicine to prepare them for future challenges in their career pathway. In this collaboration we will increase the commune expertise on tumour types and technical expertise for target validation. This will improve the implementation of interventions across paediatric cancer and strongly reduce the timeline from bench to the bedside.
| Charite - Universitaetsmedizin Berlin | 252 788 € |
| Deutsches Krebsforschungszentrum Heidelberg | 505 577 € |
| Gadeta B.V. | 177 080 € |
| Institut Curie | 549 604 € |
| Institute of Cancer Research: the Royal Cancer Hospital LBG | 303 173 € |
| Istituto Ortopedico Rizzoli | 261 500 € |
| Ludwig-Maximilians-Universitaet Muenchen | 252 788 € |
| Prinses Maxima Centrum Voor Kinderoncologie B.V. | 885 400 € |
| ST. Anna Kinderkrebsforschung GmbH | 264 207 € |
| ST Anna Kinderkrebsforschung Verein | 0,00 € |
| Universitat Zurich | 281 277 € |
| Universiteit Gent | 256 320 € |
https://cordis.europa.eu/project/id/956285
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.